CSL Limited Stock price

Equities

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
287.9 AUD +0.55% Intraday chart for CSL Limited +4.21% +0.44%
Sales 2024 * 14.72B 22.62B Sales 2025 * 15.98B 24.56B Capitalization 90.78B 139B
Net income 2024 * 2.71B 4.17B Net income 2025 * 3.29B 5.05B EV / Sales 2024 * 6.83 x
Net Debt 2024 * 9.83B 15.1B Net Debt 2025 * 8.61B 13.23B EV / Sales 2025 * 6.22 x
P/E ratio 2024 *
33.2 x
P/E ratio 2025 *
27.4 x
Employees 32,065
Yield 2024 *
1.41%
Yield 2025 *
1.66%
Free-Float 99.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.55%
1 week+4.21%
Current month+0.59%
1 month+0.81%
3 months+0.44%
6 months+14.24%
Current year+0.44%
More quotes
1 week
280.65
Extreme 280.65
289.76
1 month
275.00
Extreme 275
289.76
Current year
275.00
Extreme 275
306.42
1 year
228.65
Extreme 228.65
312.99
3 years
228.65
Extreme 228.65
319.78
5 years
189.14
Extreme 189.14
342.75
10 years
63.77
Extreme 63.77
342.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-05-31
Director of Finance/CFO 59 20-09-30
Chief Tech/Sci/R&D Officer 62 20-09-30
Members of the board TitleAgeSince
Director/Board Member 69 19-12-08
President 68 90-06-30
Director/Board Member 61 21-08-18
More insiders
Date Price Change Volume
24-03-28 287.9 +0.55% 638,665
24-03-27 286.4 +1.37% 484,437
24-03-26 282.5 -0.43% 383,975
24-03-25 283.7 +0.98% 581,262
24-03-22 280.9 +1.68% 1,380,370

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
187.9 USD
Average target price
197.8 USD
Spread / Average Target
+5.27%
Consensus
  1. Stock
  2. Equities
  3. Stock CSL Limited - Australian S.E.